However, some challenges, such as variable and often low level of BCMA expression on MM cells and antigen-negative tumor escape after initial BCMA-targeted immunotherapy, result in unsustained remission [31]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.